menu
    • menu

    Company profile for Sunesis Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept...
    Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sunesis PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    395 Oyster Point Blvd. Ste. 400 South San Francisco, CA 94080
    Telephone
    Telephone
    650-266-3716
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sunesis.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/sunesis-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/sunesispharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viracta Therapeutics Announces Closing of Merger with Sunesis and $65M
    Viracta Therapeutics Announces Closing of Merger with Sunesis and $65M

    24 Feb 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/viracta-therapeutics-announces-closing-of-merger-with-sunesis-pharmaceuticals-and-65m-private-placement/?s=79

    BIOSPACE
    24 Feb 2021
    Share Share
    Sunesis Pharmaceuticals and Viracta Announce Definitive Merger Agreement
    Sunesis Pharmaceuticals and Viracta Announce Definitive Merger Agreement

    30 Nov 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/11/30/2136415/0/en/Sunesis-Pharmaceuticals-and-Viracta-Therapeutics-Announce-Definitive-Merger-Agreement.html

    GLOBENEWSWIRE
    30 Nov 2020
    Share Share
    Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data
    Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data

    12 Oct 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/10/12/2106757/0/en/Sunesis-Pharmaceuticals-Announces-Presentation-of-SNS-510-Preclinical-Data-at-the-32nd-EORTC-NCI-AACR-Symposium-on-Molecular-Targets-and-Cancer-Therapeutics.html

    GLOBENEWSWIRE
    12 Oct 2020
    Share Share
    Sunesis Announces Proposed Public Offering of Common Stock
    Sunesis Announces Proposed Public Offering of Common Stock

    29 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/28/2069017/0/en/Sunesis-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    29 Jul 2020
    Share Share
    Sunesis Pharmaceuticals Provides Corporate Update
    Sunesis Pharmaceuticals Provides Corporate Update

    07 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/07/2058909/0/en/Sunesis-Pharmaceuticals-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    07 Jul 2020
    Share Share
    Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
    Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program

    23 Jun 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/06/23/2051898/0/en/Sunesis-Pharmaceuticals-Announces-Clinical-Update-on-Vecabrutinib-Program.html

    GLOBENEWSWIRE
    23 Jun 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search